Impact of Growth Factor Independence 1 in Human T-Cell Lymphomas; Pathogenic Potential Identified by Insertional Mutagenesis in a Murine T-Cell Lymphoma Model.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 5047-5047
Author(s):  
Magdalena Julia Dabrowska ◽  
Karen Dybkaer ◽  
Preben Johansen ◽  
Hans Erik Johnsen ◽  
Finn Skou Pedersen

Abstract Abstract 5047 Introduction The transcriptional repressor and oncogene Growth factor independence 1 (Gfi1) has a major oncogenic potential and is aberrantly expressed in murine lymphomas and several human cancers. Gfi1 is a key regulator of stem cell quiescence and plays a significant role in T-cell development, lineage commitment, and influences development of maturate granulocytes and monocytes. The genomic locus on murine chromosome 5 encoding Gfi1 is a frequent integration locus activated in T-cell lymphomas induced by the SL3-3 Murine Leukemia Virus (MLV) as well as other MLVs, indicating that Gfi1 is essential in development of these tumors. In the SL3-3 induced T-cell lymphoma model, retroviral insertions in the Gfi1 3'UTR have been demonstrated to decouple microRNA-mediated posttranscriptional regulation of protein expression (Dabrowska et al, 2009) further supporting its role in lymphomagenesis. In human cancers, Gfi1 protein expression has been observed in HTLV-1 induced ATLL and SCLC but no knowledge exists on how Gfi1 contributes to initiating and maintaining human T-cell lymphomas. Methods Gfi1 gene and protein expression patterns were determined in precursor and mature human T-cell lymphomas by real time PCR and Western blot analysis. Furthermore, localization and expression patterns of the Gfi1 protein was determined in the human T-cell lymphomas by immunohistochemical staining with Gfi1 antibodies and compared to similar staining of MLV induced tumors. Results Our results demonstrated that Gfi1 mRNA and protein levels vary significantly among the human T-cell lymphomas, and do not always show a direct proportional pattern. Thus, Gfi1 mRNA expression can be relatively high without resulting in a corresponding high protein expression, suggesting that a microRNA mediated posttranscriptional regulation exists in some tumors but may be disrupted in others. Furthermore, an additional Gfi1 protein variant was identified in one of the T-cell lymphoma entities. Immunohistochemical staining demonstrated varying Gfi1 protein expression in both nucleus and cytoplasm in the T-cell lymphomas and different distributions of the protein within the tumor and tumor cells were observed among samples. Staining of normal human tonsil demonstrated Gfi1 protein to be localized in the cytoplasm. We hypothesise that regulation of Gfi1 may include shuttling between cytoplasm and nucleus and that lymphomagenesis enables unlimited nuclear access. Conclusion Our data shows that deregulated Gfi1 expression plays a major role in the development of MLV induced lymphomas and strongly indicates that retroviral insertional mutagenesis in murine models of human NHLs can be used to identify new genes involved in lymphomagenesis and, by use of functional assays, their impact on human lymphomas can be evaluated. Disclosures No relevant conflicts of interest to declare.

1981 ◽  
Vol 154 (6) ◽  
pp. 1957-1964 ◽  
Author(s):  
M Robert-Guroff ◽  
F W Ruscetti ◽  
L E Posner ◽  
B J Poiesz ◽  
R C Gallo

A monoclonal antibody specific for the internal p19 protein of a type-C retrovirus (HTLV) isolated from human neoplastic T cells has been developed. Its specificity has been shown by radioimmune precipitation and by affinity chromatography of iodinated HTLV proteins. By indirect immune fluorescence this antibody recognizes only HTLV-producing cells. Examination of cells from patients with cutaneous T cell lymphomas and leukemias and with other types of lymphomas and leukemias indicated that HTLV p19 expression is rare. The monoclonal antibody will be useful in determining the natural reservoir of HTLV, possibly in a subset of mature T cell neoplasias.


1981 ◽  
Vol 154 (2) ◽  
pp. 333-346 ◽  
Author(s):  
L E Posner ◽  
M Robert-Guroff ◽  
V S Kalyanaraman ◽  
B J Poiesz ◽  
F W Ruscetti ◽  
...  

Sera from patients with cutaneous T cell lymphoma and leukemia were screened for the presence of natural antibody to the human T cell lymphoma (leukemia) virus, HTLVCR, using a solid-phase radioimmunoassay. Sera from two patients, including patient CR, from whose cultured T lymphoblastic cell line (HUT102), the retrovirus HTLVCR was isolated, reacted specifically with proteins of HTLVCR. Serum from patient CR also reacted specifically with proteins of HTLVMB, an independent but highly related retroviral isolate from a patient with Sezary T cell leukemia. The specificity for HTLVCR proteins was demonstrated by solid-phase immunocompetition assays and competition radioimmunoprecipitation assays. Analysis of radioimmunoprecipitates indicated that the natural antibodies were directed against HTLVCR core proteins with molecular weights of 24,000 and 19,000 (p24 and p19). Whereas the serum reactivities for HTLVCR proteins were shown to be highly specific, additional reactivities seen against proteins of animal retroviruses including GaLV, SSV, FeLV, and BaEV were clearly shown not to be viral specific but rather were due to reactivity with cellular antigens contaminating the viral preparations or with related antigens present in fetal calf serum. These results demonstrating natural antibodies to HTLVCR provide the first evidence for a specific antibody response to a retrovirus in humans.


2014 ◽  
Vol 9 ◽  
pp. BMI.S16553 ◽  
Author(s):  
Suketu Patel ◽  
Derek Murphy ◽  
Eugenia Haralambieva ◽  
Zainalabideen A. Abdulla ◽  
Kah Keng Wong ◽  
...  

FAS-associated protein with death domain (FADD) is a major adaptor protein involved in extrinsic apoptosis, embryogenesis, and lymphocyte homeostasis. Although abnormalities of the FADD/death receptor apoptotic pathways have been established in tumorigenesis, fewer studies have analyzed the expression and role of phosphorylated FADD (pFADD). Our identification of FADD as a lymphoma-associated autoantigen in T-cell lymphoma patients raises the possibility that pFADD, with its correlation with cell cycle, may possess role(s) in human T-cell lymphoma development. This immunohistochemical study investigated pFADD protein expression in a range of normal tissues and lymphomas, particularly T-cell lymphomas that require improved therapies. Whereas pFADD was expressed only in scattered normal T cells, it was detected at high levels in T-cell lymphomas (eg, 84% anaplastic large cell lymphoma and 65% peripheral T cell lymphomas, not otherwise specified). The increased expression of pFADD supports further study of its clinical relevance and role in lymphomagenesis, highlighting phosphorylation of FADD as a potential therapeutic target.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 965-965
Author(s):  
Julie Teruya-Feldstein ◽  
Takahiro Maeda ◽  
Alexander Filatov ◽  
P.P. Pandolfi

Abstract Background: POKEMON (for POK, Erythroid, Myeloid ONtogenic factor) has recently been shown to be a novel proto-oncogene, playing a key role in cellular transformation and repression of ARF. Pokemon overexpression leads to overt oncogenic transformation both in vitro and in vivo in transgenic mice. Because these transgenic mice developed T-cell lymphoma we sought to expand our original screening analyses. We intially showed POKEMON expression in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) and co-expression of BCL6 and POKMEON showed higher proliferation and predicted for better overall survival in DLBCL (Nature 433, 278–285). Nodular lymphocyte predominant Hodgkin Lymphoma (NLPHL) is another tumor that expresses BCL6 and shows localization to L&H tumor cells. We therefore sought to compare POKEMON protein expression in NLPHL and Classical Hodgkin Lymphoma (cHL) cases. Design: Stains for POKEMON were performed with the anti-POKEMON hamster monoclonal antibody (clone 13E9). Sections of reactive human tonsil were stained as controls showing localization to squamous epithelium and reactive germinal centers as well as paracortical regions. For NLPHL, the cohort comprised of 19 males, 2 females; for cHL 16 males, 14 females. 20 NLPHL and 30 cHL tissue biopsies were stained using whole sections. Intensity and percent positivity of malignant L&H cells and Reed-Sternberg (RS) cells as well as surrounding reactive lymphocytes was scored. Expression in T-cell lymphomas was expanded to include a total of 84 cases analyzed by tissue microarray (TMA) that included: 8 ALCL (Anaplastic Large Cell Lymphoma), 11 AILT (Angioimmunoblastic T-cell Lymphoma), 17 T-ALL (T Lymphoblastic Lymphoma), 43 PTCL (Peripheral T-cell Lymphoma), 3 T/NK (Nasal type T/NK cell Lymphoma), and 2 PTCL, NOS (Not Otherwise Subclassified). Tumor cells in T-cell lymphomas and HL were scored and defined as 0 (negative), 1 (scattered <50%, weak positive), and 2 (diffuse >50%, strong positive) with a nuclear localization pattern. Results: For NLPHL, 18/20 (90%) cases showed diffuse strong positivity in >50% of malignant L&H tumor cells whereas in cHL cases, 6/30 (20%) cases showed diffuse strong positivity in >50% of malignant RS tumor cells for POKEMON protein expression. In T-cell lymphomas, POKEMON expression was strongest in ALCL (6/8, 75%) and AILD (7/11, 74%) compared to the other subtypes. In contrast, BCL6 protein expression was positive in 12/20 (60%) cases which showed weak, scattered to diffuse strong positivity in L&H tumor cells and 1/30 (3%) with scattered weak reactivity in cHL malignant RS cells Conclusion: POKEMON is co-expressed with BCL6 in malignant L&H tumor cells in NLPHL but not in cHL. Pokemon’s critical role in cellular transformation makes it an attractive target for therapeutic intervention in NLPHL.


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 1287-1287
Author(s):  
Lingyun Geng ◽  
Xiangxiang Zhou ◽  
Xinyu Li ◽  
Kang Lu ◽  
Peipei Li ◽  
...  

Abstract Introduction: T-cell lymphomas are lymphoid malignancies with aggressive clinical course and poor prognosis. The etiology remains to be elucidated, and no uniformed therapeutic strategies have been achieved. Increasing evidence has shown that aberrant activation of signal transducer and activator of transcription-3 (STAT3) and suppressor of cytokine signaling 3 (SOCS3) may be associated with the development of T-cell lymphomas. The Hedgehog (Hh) pathway, aberrantly activated in a number of tumors, has been extensively studied with respect to its interaction with other oncogenic pathways. It has been established that inhibition of Hh pathway has antitumor efficacy in T-cell lymphoma cells. Gli1 inhibitor GANT61 is a promising Hh pathway inhibitor against cancer therapy. We speculated that GANT61 has antitumor activity for T-cell Lymphoma cells and the activity is associated with down-regulation of phosphorylated STAT3 (p-STAT3) and SOCS3. This study investigated the inhibitory effects and the mechanism of action of GANT61 on T-cell lymphoma cells. Methods: The paraffin-embedded tissues from thirty-five T-cell lymphoma patients were collected prior to therapeutic intervention. The expression of Gli1, p-STAT3 and SOCS3 in T-cell lymphoma tissues and cell lines (Jurkat, Karpass299 and Myla3676 cells) was investigated by Immunohistochemistry (IHC) and Western-blot respectively. Reactive hyperplasia of lymph node tissues and peripheral blood T cells from healthy volunteers served as control respectively. Cytotoxicity of GANT61 on the three cells was assessed by the cell counting kit-8 (CCK-8) assay after a 48-hour GANT61 treatment at different concentrations, and half-maximal inhibitory concentration (IC50) values were calculated respectively. Effect of GANT61 on apoptosis of these cells was evaluated by AnexinV-PE/7AAD assay, and protein expression of Gli1, p-STAT3, STAT3 and SOCS3 was detected by Western-blot after a 24-hour GANT61 treatment at different concentrations. To confirm the specific role of Gli1, lentivirus-mediated RNA interference was carried out to knockdown Gli1 gene in the three cells. Proliferation and apoptosis of normal and stable transfected siGli1 cells were assessed by CCK8 assay and AnexinV/7AAD assay respectively. Protein expression of Gli1, p-STAT3 and SOCS3 was assessed by Western-blot analysis after the genetically intervention. Results: Western-blot and IHC analysis showed that the expression of Gli1, p-STAT3 and SOCS3 protein was up-regulated in T-cell lymphoma cells and tissues compared with peripheral blood T cells from healthy volunteers and tissues from patients with reactive hyperplasia of lymph node respectively (Figure 1A-B). Moreover, the interaction of p-STAT3 and Gli1 in Jurkat, Myla3676 and Karpass299 cells were observed in the Western- blot analysis of Co-Immunoprecipitation (Co-IP) (Figure 1C). Viability of Jurkat, Karpass299 and Myla3676 cells decreased in a dose-dependent manner after a 48-hour incubation of GANT61 (Figure 2A). GANT61 induced apoptosis and decreased the protein expression of Gli1, p-STAT3 and SOCS3 in the three cells after a 24-hour treatment of GANT61 in a dose-dependent manner (Figure 2B-C). Furthermore, knockdown of Gli1 by lentivirus-mediated RNA interference inhibited the proliferation and induced apoptosis (Figure 3A-B), as well as downregulated the protein expression of Gli1, p-STAT3 and SOCS3 in these cells (Figure 3C). Conclusions: These results showed that protein expression of Gli1, p-STAT3 and SOCS3 was up-regulated in T-cell lymphoma tissues and cell lines. Inhibition of Gli1 by GANT61 or RNA interference could attenuate proliferation and induce apoptosis of Jurkat, Karpass299 and Myla3676 cells. Moreover, the p-STAT3 and SOCS3 were decreased accompanied with the inhibition of Gli1. Our findings indicated a potential mechanism for the antitumor activity of GANT61 which might inhibit viability of T-cell lymphoma cells at least partially by down-regulating p-STAT3 and SOCS3 pathways. The crosstalk between Hh pathway and STAT3 pathway in T cell lymphomas deserves more exploration. Targeting the Hh pathway may be a novel therapeutic strategy for T-cell lymphomas. Figure 1. Figure 1. Figure 2. Figure 2. Figure 3. Figure 3. Disclosures No relevant conflicts of interest to declare.


2021 ◽  
Vol 9 (1) ◽  
pp. 5
Author(s):  
Krishna C. Thandra ◽  
Adam Barsouk ◽  
Kalyan Saginala ◽  
Sandeep Anand Padala ◽  
Alexander Barsouk ◽  
...  

Non-Hodgins’s lymphoma (NHL) is the most common hematological malignancy worldwide, accounting for nearly 3% of cancer diagnoses and deaths. NHL is the seventh most prevalent cancer and has the sixth highest mortality among cancers in the US. NHL accounts for 4% of US cancer diagnoses, and incidence has increased 168% since 1975 (while survival has improved 158%). NHL is more common among men, those >65 years old, and those with autoimmune disease or a family history of hematological malignancies. NHL is a heterogenous disease, with each subtype associated with different risk factors. Marginal zone lymphoma (MZL) is strongly associated with Sjogren’s syndrome (SS) and Hashimoto’s thyroiditis, while peripheral T-cell lymphoma (PTCL) is most associated with celiac disease. Occupational exposures among farm workers or painters increases the risk of most of the common subtypes. Prior radiation treatment, obesity, and smoking are most highly associated with diffuse large B-cell lymphoma (DLBCL), while breast implants have been rarely associated with anaplastic large cell lymphoma (ALCL). Infection with Epstein–Barr Virus (EBV) is strongly associated with endemic Burkitts lymphoma. HIV and human herpes virus 8 (HHV-8), is predisposed to several subtypes of DLBCL, and human T-cell lymphoma virus (HTLV-1) is a causative agent of T-cell lymphomas. Obesity and vitamin D deficiency worsen NHL survival. Atopic diseases and alcohol consumption seem to be protective against NHL.


Blood ◽  
2003 ◽  
Vol 102 (6) ◽  
pp. 2213-2219 ◽  
Author(s):  
Marcel W. Bekkenk ◽  
Maarten H. Vermeer ◽  
Patty M. Jansen ◽  
Ariënne M. W. van Marion ◽  
Marijke R. Canninga-van Dijk ◽  
...  

Abstract In the present study the clinicopathologic and immunophenotypic features of 82 patients with a CD30– peripheral T-cell lymphoma, unspecified, presenting in the skin were evaluated. The purpose of this study was to find out whether subdivision of these lymphomas on the basis of cell size, phenotype, or presentation with only skin lesions is clinically relevant. The study group included 46 primary cutaneous CD30– large cell lymphomas and 17 small/medium-sized T-cell lymphomas as well as 17 peripheral T-cell lymphomas with both skin and extracutaneous disease at the time of diagnosis. Patients with primary cutaneous small- or medium-sized T-cell lymphomas had a significantly better prognosis (5-year-overall survival, 45%) than patients with primary cutaneous CD30– large T-cell lymphomas (12%) and patients presenting with concurrent extracutaneous disease (12%). The favorable prognosis in this group with primary cutaneous small- or medium-sized T-cell lymphomas was particularly found in patients presenting with localized skin lesions expressing a CD3+CD4+CD8– phenotype. In the primary cutaneous T-cell lymphoma (CTCL) group and in the concurrent group, neither extent of skin lesions nor phenotype had any effect on survival. Our results indicate that peripheral T-cell lymphomas, unspecified, presenting in the skin have an unfavorable prognosis, irrespective of the presence or absence of extracutaneous disease at the time of diagnosis, cell size, and expression of a CD4+ or CD8+ phenotype. The only exception was a group of primary cutaneous small- or medium-sized pleomorphic CTCLs with a CD3+CD4+CD8– phenotype and presenting with localized skin lesions.


2019 ◽  
Vol 54 (10) ◽  
pp. 2117-2119 ◽  
Author(s):  
Adele P. Williams ◽  
Jerry E. Stewart ◽  
Laura L. Stafman ◽  
Jamie M. Aye ◽  
Elizabeth Mroczek-Musulman ◽  
...  

2018 ◽  
Vol 11 (1) ◽  
pp. 212-215 ◽  
Author(s):  
Yota Sato ◽  
Taku Fujimura ◽  
Yumi Kambayashi ◽  
Akira Hashimoto ◽  
Setsuya Aiba

Bexarotene is a third-generation retinoid X receptor-selective retinoid that is widely used for the early treatment of advanced-stage cutaneous T-cell lymphomas. In this report, we describe a case of successful treatment of advanced primary cutaneous peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) with oral bexarotene monotherapy. After the administration of oral bexarotene at a dose of 300 mg/m2/day, all skin lesions and lymph nodes regressed, and complete remission was achieved for 1 year. Our case suggested that bexarotene monotherapy could be one of the possible therapies for the treatment of primary cutaneous PTCL-NOS.


Sign in / Sign up

Export Citation Format

Share Document